<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The epidemiology of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, recent clinical findings that highlight the importance of actively managing <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, and recommendations for initiating and maintaining iron chelation therapy (ICT) are summarized </plain></SENT>
<SENT sid="1" pm="."><plain>SUMMARY: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are a variety of <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> with differing time courses </plain></SENT>
<SENT sid="2" pm="."><plain>Disease morbidities are primarily due to cytopenias and evolution to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">Iron overload</z:e> is a serious complication in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> due to the long-term use of red blood cell transfusions in patients with symptomatic <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical consequences of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> include end-organ damage and dysfunction, an increased frequency of transplant-related complications, and <z:mp ids='MP_0008770'>reduced survival rates</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>To prevent these complications, recommendations for initiating and maintaining ICT should be followed by clinicians caring for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: As current therapeutic options for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> do not always reduce the transfusion burden, many patients will still need long-term transfusion therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Strategies for the management of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be considered early in the disease course and in appropriate patients in order to prevent negative clinical outcomes associated with excessive iron accumulation </plain></SENT>
</text></document>